Who is sponsoring NCT02761811?

NCT02761811 is sponsored by SyMap Medical (Suzhou), Ltd..

What drugs are being tested in NCT02761811?

Interventions in NCT02761811: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator.

What condition does NCT02761811 study?

NCT02761811 studies Hypertension.

Is NCT02761811 still recruiting?

NCT02761811 is currently active, enrolled. Last updated 2 August 2023.

Last reviewed 2023-08-02 · How we verify

NCT02761811: SMART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sympathetic Mapping/ Ablation of Renal Nerves Trial

Active, enrolled NA Last updated 2 August 2023

What this trial tests

NA trial testing SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator in Hypertension in 220 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 June 2016

Primary endpoint
25 August 2022

31 December 2026

Quick facts

Lead sponsor	SyMap Medical (Suzhou), Ltd.
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	220
Start date	30 June 2016
Primary completion	25 August 2022
Estimated completion	31 December 2026
Sites	15 locations across China

Drugs / interventions tested

SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

SyMap Medical (Suzhou), Ltd.

Who can join

Adults 18 to 65, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of targeted renal sympathetic denervation using SyMapCath I® and SYMPIONEER S1® Stimulator/ Generator in patients with essential hypertension for at least 6 months of the disease history and pharmacotherapy, however, their blood pressure still cannot be controlled, then after standardized antihypertensive drug therapy (at least two drugs) for at least 28 days, office systolic blood pressure is still ≥ 150mmHg, ≤180mmHg.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Renal Denervation in Asia: Consensus Statement of the Asia Renal Denervation Consortium.
Kario K, Kim BK, Aoki J, Wong AY, et al · · 2020 · cited 54× · PMID 32008432 · DOI 10.1161/hypertensionaha.119.13671
Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial.
Wang J, Yin Y, Lu C, Lu Z, et al · · 2024 · cited 20× · PMID 38756107 · DOI 10.1016/j.eclinm.2024.102626
Renal denervation in the management of hypertension.
Lauder L, Kandzari DE, Lüscher TF, Mahfoud F. · · 2024 · cited 11× · PMID 38629418 · DOI 10.4244/eij-d-23-00836
Rationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial (SMART) for the Treatment of Hypertension: a Prospective, Multicenter, Single-Blind, Randomized and Sham Procedure-Controlled Study.
Wang J, Sun N, Ge J, Jiang H, et al · · 2023 · cited 9× · PMID 36042146 · DOI 10.1007/s12265-022-10307-z
Renal Denervation Effects on Blood Pressure in Resistant and Uncontrolled Hypertension: A Meta-Analysis of Sham-Controlled Randomized Clinical Trials.
Soleimani H, Sattartabar B, Parastooei B, Eshraghi R, et al · · 2025 · cited 3× · PMID 40022571 · DOI 10.1002/clc.70104
Present Evidence of Determinants to Predict the Efficacy of Renal Denervation.
Zhou H, Xu Y, Chen W, Wang L, et al · · 2022 · cited 1× · PMID 35992203 · DOI 10.1155/2022/5694127
A scoping review of neuromodulation techniques for controlling blood pressure: what are the ups and downs to this approach?
Greechan PL, Koh RGL, Yoo PB. · · 2025 · PMID 40814063 · DOI 10.1186/s42234-025-00181-w

Verify or expand the search:

Other trials of SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator

Trials testing the same drug.

NCT04872114 — Sympathetic Mapping/ Ablation of Renal Nerves Trial - Hemodialysis · NA · unknown

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other SyMap Medical (Suzhou), Ltd. trials

Trials by the same sponsor.

NCT07336433 — SMART-IC-Pilot Study · NA · not yet recruiting
NCT03765307 — Bronchial Ablation for Treatment of Asthma (BATA) Trial · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02761811 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SyMap Medical (Suzhou), Ltd.
Last refreshed: 2 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02761811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing